Telomerase as a novel and potentially selective target for cancer chemotherapy

Area of Science:

• Molecular Biology
• Cell Biology
• Cancer Research

Background:

• Telomeres are protective structures at eukaryotic chromosome ends.
• Telomerase maintains telomeres in germ cells but is silenced in most human somatic cells.
• Telomere shortening triggers cellular senescence and growth arrest.

Purpose of the Study:

• To evaluate telomerase as a selective anti-cancer drug target.
• To review proof-of-principle experiments supporting telomerase inhibition in cancer.
• To address concerns regarding telomerase-targeted cancer therapy.

Main Methods:

• Review of existing proof-of-principle experiments.
• Analysis of telomere length dynamics in cancer cells.
• Discussion of telomerase's role in cancer development and progression.

Main Results:

• Most human cancers (approx. 80%) reactivate telomerase to bypass senescence.
• Many diagnosed cancers exhibit critically short telomeres, increasing vulnerability to telomerase inhibition.
• Normal cells possess sufficient telomere reserves, suggesting potential selectivity for anti-cancer drugs targeting telomerase.

Conclusions:

• Telomerase is a promising and potentially selective anti-cancer drug target, particularly for cancers with short telomeres.
• Evidence supports the therapeutic potential of inhibiting telomerase in specific cancer subsets.
• Further research and consideration of concerns are needed for effective telomerase-targeted drug design.